News Image

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Provided By GlobeNewswire

Last update: Feb 18, 2025

– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients discontinued all immunosuppressants and are off steroids as of the latest follow-up –

Read more at globenewswire.com

CABALETTA BIO INC

NASDAQ:CABA (5/30/2025, 8:00:01 PM)

After market: 1.8699 0 (-0.01%)

1.87

-0.04 (-2.09%)



Find more stocks in the Stock Screener

CABA Latest News and Analysis

ChartMill News Image16 days ago - ChartmillTop movers in Friday's pre-market session

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Mentions: GTI GLOB EVLV AYTU ...

ChartMill News Image17 days ago - ChartmillThese stocks are gapping in today's session

Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.

Mentions: BOOT GTI FL TE ...

Follow ChartMill for more